BOSTON, June 22, 2024 (GLOBE NEWSWIRE) — Novotech, the global full-service contract clinical research organization (“CRO”) working with biotechnology companies to accelerate all stages of product development advanced and innovative therapeutics, published a comprehensive research report entitled Endometrial cancer – Global Clinical Trial Landscape.
The report provides key insights and data on the global clinical trial landscape for uterine cancer, primarily endometrial cancer (“EC”), with a focus on prevalence, funding landscape , emerging trends, treatments, trial density, and patient recruitment for trial planning and research.
Since 2018, more than 1,200 CE clinical trials have been initiated globally, with North America and Asia Pacific contributing 39% and 33% of trials, respectively, followed by Europe at 22%.
EC is the second most common cause of death and the fourth leading cause of death among gynecological cancers worldwide. In 2022 alone, nearly 420,370 new cases of CE were reported worldwide, with approximately 97,720 deaths.
- Asia (167,430) accounts for almost 40% of global EC cases in 2022
- Europe (124,874)
- North America (73,977)
In Asia :
- Mainland China recorded the highest incidence with 77,722 cases
- The United States ranks second in the world in incidence with 66,055 cases, as well as the highest ASD of 22.5 per 100,000 population
- In Europe, Russia has the third highest incidence rate, with 29,852 cases
Currently, the standard of care for EC is surgery with partial or total hysterectomy and bilateral salpingo-oophorectomy (“HT/SOB”). For patients with recurrent EC, treatments vary depending on the extent of the cancer and the success of previous treatments, including surgery, radiation therapy, and systemic therapy such as chemotherapy and hormone therapy.
The report states that projections for the EC show an increase in new cases over the next 25 years, possibly exceeding 600,000 new cases annually by 2044.
This demand for treatments has driven an increase in CE clinical trial activity globally between 2014 and 2023, with the Asia-Pacific region seeing the largest increase with a compound annual growth rate (“CAGR”) of 22 .9%. Countries in the “Rest of the World” (“ROW”) region follow closely at 14.9%, while the North America and Europe regions show a stable growth rate, respectively at 9.7%. and 5.2%.
Likewise, the funding landscape is strong, with the United States dominating venture capital funding of CE research between 2019 and 2023, followed by China, with investments totaling $2,129 million and $894 million. Public funding initiatives in Australia and the United States have focused on expanding and improving the quality of care.
Other key trends in clinical trials and treatment developments are highlighted in the report:
- In North America, the United States was most active in conducting trials, while mainland China was most active in the Asia-Pacific region, followed by Australia and Korea from South.
- Trial phase trends show that North America and Asia Pacific are conducting a greater number of early and mid-phase trials (phases 1 and 2), while Europe and the RoM focus on late-stage trials (phase 3).
- Asia Pacific has the shortest median recruitment period (15.1 months) and the highest median recruitment rate (1.1 subjects per center per month), indicating effective patient recruitment.
- There are nearly six drugs in preclinical stages, 15 in phase I trials, and 12 in phase I and II trials combined.
- In phase III trials, programmed cell death ligand 1 inhibitor 1 dominates the mechanism of action (“MA”), followed by programmed cell death protein 1 antagonist and inhibitor poly [ADP-ribose] polymerase 1.
- Marketed drugs for CE primarily target DNA synthesis inhibitors, progesterone receptor agonists, and tubulin inhibitors.
Novotech’s team of analysts write these expert reports on a monthly basis. They are completely free. In addition to the information mentioned above, the report also includes an in-depth SWOT analysis aimed at guiding the strategic decision-making of biotechnology companies, as well as research opportunities and challenges. They address the potential and actual barriers facing biotechnology companies in specific therapeutic areas, hoping to positively influence and inform clinical trial decision-making to improve outcomes. success rate of new treatments.
Download the report here
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global, full-service contract clinical research organization (“CRO”) dedicated to partnering with biotechnology companies to accelerate all stages of drug development. advanced and innovative therapeutic products.
Recognized for its major contributions to the industry, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and the Asia-Pacific Contract Research Organization Company of the Year Award” since 2006.
The Company offers a full range of services, including laboratories, phase I facilities, drug development consulting and regulatory expertise. She has successfully completed more than 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 offices and a dedicated team of more than 3,000 professionals worldwide, Novotech is a trusted integral and strategic partner.
For more information or to speak with a member of the team of experts, visit www.Novotech-CRO.com
A photo accompanying this release is available at the following address: https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ce74ba-6793-437c-9766-0e04b71255ce
